Want to join the conversation?
$ABBV said that it delivered strong performance in the 4Q15, exceeding original sales, margin expansion, and earnings projections for the quarter. The company also stated it delivered 22% global operational sales growth in 2015 and its earnings per share was up 29% during 2015.
Biodefense therapeutics firm $PIP announced an all-stock merger with biotech Altimmune. The respective boards of the two companies unanimously approved the merger.
$YHOO is reporting today after market close. Nobody cares about this stock.